Molecular Details

DICL_CP_0349167 - 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Basic Molecular Information

Basic Information

DICL ID

DICL_CP_0349167

PubChem CID

77999

Molecular Formula

C₁₈H₁₉N₃O₃S

Molecular Weight

357.435 g/mol

Synonyms/Alias

[rosiglitazone; 122320-73-4; Avandia; Rosiglizole; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2;4-dione; Brl-49653; Brl 49653; Rezult; Gaudil; Rosvel; BRL49653; TDZ 01; rosiglitazon...[rosiglitazone; 122320-73-4; Avandia; Rosiglizole; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2;4-dione; Brl-49653; Brl 49653; Rezult; Gaudil; Rosvel; BRL49653; TDZ 01; rosiglitazona; rosiglitazonum; Avandamet; Avandaryl; rosiglitazone (Avandia); DTXSID7037131; C18H19N3O3S; CHEBI:50122; UNII-05V02F2KDG; NSC-758698; 05V02F2KDG; TDZ-01; HSDB 7555; 2;4-Thiazolidinedione; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2;4-thiazolidinedione; MFCD00871760; Rosigilitazone; 2;4-thiazolidinedione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2;4-thiazolidinedione-2-butenedioate; DTXCID5017131; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1;3-thiazolidine-2;4-dione; Rosiglitazone (INN); NSC 758698; NCGC00095124-01; BRL 49653C; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2;4-thiazolidinedione; 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1;3-thiazolidine-2;4-dione; ROSIGLITAZONE [INN]; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1;3-thiazolidine-2;4-dione; ROSIGLITAZONE (IARC); ROSIGLITAZONE [IARC]; ROSIGLITAZONE (MART.); ROSIGLITAZONE [MART.]; 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2;4-dione; Rosiglitazone [INN:BAN]; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2;4-dione; 5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2;4-THIAZOLIDINEDIONE; CAS-122320-73-4; SR-01000763023; Rosiglitazon; Rosigltazone; Rosi; Rosiglitazone base; 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)-1;3-thiazolidine-2;4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2;4-dione; RGZ; Gaudil (TN); Rosiglitazone- Bio-X; Spectrum_001703; 1217260-35-9; Spectrum2_001241; Spectrum3_000997; Spectrum4_001125; Spectrum5_001464; ROSIGLITAZONE [MI]; SCHEMBL5169; ROSIGLITAZONE [HSDB]; BSPBio_002693; KBioGR_001609; KBioSS_002183; ROSIGLITAZONE [VANDF]; SPECTRUM1504263; SPBio_001142; ROSIGLITAZONE [WHO-DD]; GTPL1056; ROSIGLITAZONE [EMA EPAR]; SCHEMBL14383595; KBio2_002183; KBio2_004751; KBio2_007319; KBio3_001913; A10BG02; Rosiglitazone; >=98% (HPLC); HMS1922J11; HMS2094O13; HMS3649G08; HMS3656K16; HMS3744M11; HMS3871L03; HMS3884N08; Pharmakon1600-01504263; BCP03047; Tox21_111434; BDBM50030474; CCG-39102; HB2556; NSC758698; STL350047; AKOS015894872; O-De-Me; 2-O-B-D-galactopyranoside; Tox21_111434_1; AC-3459; BCP9000017; CS-1088; DB00412; SB17326; NCGC00095124-02; NCGC00095124-03; NCGC00095124-04; NCGC00095124-05; NCGC00095124-06; NCGC00095124-08; BR164372; HY-17386; SY031184; BCP0726000232; NS00008920; R0106; S2556; SW197573-6; 6P-065; D08491; S00306; AB00698473-15; AB00698473-17; AB00698473-18; AB00698473-19; AB00698473_20; AB00698473_21; AB00698473_22; AB00698473_23; Q424771; Q-201681; SR-01000763023-5; SR-01000763023-6; BRD-A97437073-001-02-3; BRD-A97437073-001-03-1; BRD-A97437073-001-04-9; SR-01000763023-12; (+-)-5-(p-(2-(methyl-2-pyridylamino)ethoxy)benzyl)-2;4-thiazolidinedione; (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2;4-thiazolidinedion; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2;4-dione; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2;4dione; IDMB (1uM BRL49653; 1uM Dexamethasone; 0.5uM IBMX; 10ug/mL Insulin); (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2;4-thiazolidinedione; 2;4-Thiazolidinedione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2;4-dione; 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2;4-thiazolidinedione; 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2;4-thiazolidinedione; 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1;3-thiazolidine-2;4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2;4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2;4-dione]

InChI Key

YASAKCUCGLMORW-UHFFFAOYSA-N

InChI

InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-...

IUPAC Name

5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

CAS Number

122320-73-4

Structure Information

Chemical Structure Visualization

SMILES Notation

2D Molecular Drawing

Carbon (C)

Hydrogen (H)

Oxygen (O)

Nitrogen (N)

Sulfur (S)

SDF

25 27 0 0 0 0 0 0 0 0999 V2000
-6.6133 -2.3847 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.3721 -1.5424 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-4.0221 -2...

Download SDF File (2236 bytes)

Experimental Data

Activity Data

Target Ion Channel

Transient receptor potential cation channel subfamily M member 3

Uniprot Accession Number

Q9HCF6

Function

Agonist

Species

Homo sapiens (Human)

IC₅₀

N/A (Not available)

EC₅₀

EC₅₀: 12000 nM

K_i

N/A (Not available)

K_d

N/A (Not available)

Inhibition

N/A (Not available)

Experimental Conditions

pH 7.4

Holding Potential

Not specified

Temperature

23 ± 2 °C

Test Method

Fluorometric Imaging Plate Reader (FLIPR) Membrane Potential Assay

Test Species

HEK293 cell (Homo sapiens embryonic kidney 293 cell)

Binding Information

Binding Site

Not specified

Binding Site Residue

Not specified

Disease Information

Related Disease

Not specified

References

DOI

10.1124/mol.110.069922

URL

N/A (Not available)

PMID

21406603

Patent

N/A (Not available)

Computed Properties

Heavy Atom Count

Rotatable Bonds

logP

2.4909

Complexity

98.0657

TPSA (Å²)

71.53

H-Bond Donors

H-Bond Acceptors

Ring Count

New Search